Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

The theory against these was launched from the Zantac claims, which are still clogging court calendars. In early October, ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

Reported earnings turn negative Expectedly, the company's reported earnings were affected by the payout for Zantac related settlements. I had last written about GSK earlier this month, following ...

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the US, claiming that its discontinued version of the heartburn drug Zantac caused cancer. It took a £1.8 ...